Comparing Continuous and Intermittent Intravenous Furosemide in Adults with Acute Decompensated Heart Failure to Assess Kidney Function, Fluid Reduction, and Outcomes

What this Trial Is About

Researchers are evaluating the best way to give intravenous loop diuretics to patients admitted with acutely decompensated heart failure ADHF. This study compares continuous infusion versus intermittent bolus infusion of furosemide, focusing on their effects on kidney function, signs of fluid overload, B-type natriuretic peptide BNP levels, and patient outcomes. The goal is to determine which administration method may better manage ADHF while considering potential risks and benefits. The study involves two groups of patients receiving either continuous intravenous infusion of furosemide or intermittent bolus intravenous infusions. These treatments are monitored during the hospital stay, typically lasting 7 to 12 days. Researchers will observe how these different infusion strategies affect heart failure symptoms, fluid removal, and kidney function over this period. Participants will be assessed regularly during hospitalization for changes in body weight, urine output, BNP levels, kidney function markers, and signs of fluid overload such as edema and lung congestion. The main outcomes include rates of cardiac death and rehospitalization for heart failure over 180 days, as well as secondary measures like length of hospital stay, use of additional medications, and improvements in congestion. The study aims to provide detailed data on how different furosemide infusion methods impact patient health and recovery.

Loop Diuretic Therapy in Acutely Decompensated Heart Failure